rituximab + MVPDL

Rituximab + MVPDL is a combination therapy consisting of rituximab, a chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes, and an agent or regimen abbreviated as "MVPDL." Rituximab works by binding to CD20 on B cells, leading to their destruction through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. It is widely used in the treatment of B-cell malignancies such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as certain autoimmune diseases. The identity of "MVPDL" is unclear based on available sources; it does not correspond to any standard chemotherapy regimen or recognized drug abbreviation in hematology/oncology literature. Therefore, this entry describes a combination where only one component (rituximab) has established pharmacological properties.